ArticleJournal of translational medicine2007
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.
Article in Journal of translational medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 111 citations in OpenAlex.
- Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.Cancer immunology, immunotherapy : CII · 2015Trial
- Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2010Trial
- Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine.Frontiers in medicine · 2026Article
- Design and Efficacy of Oncolytic Viruses and Antitumor Vaccines: A Dead End in the Immunotherapy of Pancreatic Cancer?International journal of molecular sciences · 2025Review
- Review
- Mucin-1: a promising pan-cancer therapeutic target.NPJ precision oncology · 2025Review
- Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer.Gastroenterology and hepatology from bed to bench · 2025Review
- Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.Current oncology (Toronto, Ont.) · 2024Review
- CEA vaccines.Human vaccines & immunotherapeutics · 2023Review
- Systemic treatment for advanced pancreatic cancer.World journal of gastrointestinal oncology · 2023Review
- Review
- Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine.Military Medical Research · 2022Review
- Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights.Cancer management and research · 2022Review
- The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma.Frontiers in oncology · 2022Review
- Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.World journal of gastroenterology · 2021Review
- Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches.Cancers · 2021Review
- Trials and tribulations of pancreatic cancer immunotherapy.Cancer letters · 2021Review
- Challenges and Opportunities for Pancreatic Cancer Immunotherapy.Cancer cell · 2020Review
- The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.Nature reviews. Clinical oncology · 2020Review
- Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-Nutrients · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAn open-label Phase 1 study of recombinant prime-boost poxviruses targeting CEA and MUC-1 in patients with advanced pancreatic cancer was conducted to determine safety, tolerability and obtain preliminary data on immune response and survival. PATIENTS AND
methodsTen patients with advanced pancreatic cancer were treated on a Phase I clinical trial. The vaccination regimen consisted of vaccinia virus expressing tumor antigens carcinoembryonic antigen (CEA) and mucin-1 (MUC-1) with three costimulatory molecules B7.1, ICAM-1 and LFA-3 (TRICOM) (PANVAC-V) and fowlpox virus expressing the same antigens and costimulatory molecules (PANVAC-F). Patients were primed with PANVAC-V followed by three booster vaccinations using PANVAC-F. Granulocyte-macrophage colony-stimulating factor (GM-CSF) was used as a local adjuvant after each vaccination and for 3 consecutive days thereafter. Monthly booster vaccinations for up to 12 months were provided for patients without progressive disease. Peripheral blood was collected before, during and after vaccinations for immune analysis.
resultsThe most common treatment-related adverse events were mild injection-site reactions. Antibody responses against vaccinia virus was observed in all 10 patients and antigen-specific T cell responses were observed in 5 out of 8 evaluable patients (62.5%). Median overall survival was 6.3 months and a significant increase in overall survival was noted in patients who generated anti CEA- and/or MUC-1-specific immune responses compared with those who did not (15.1 vs 3.9 months, respectively; P = .002).
conclusionPoxvirus vaccination is safe, well tolerated, and capable of generating antigen-specific immune responses in patients with advanced pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.